Menu
Enrolling by invitation NCT07517510

HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

Phase II Interventional Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: HVA.
Who it may be relevant to
Registry conditions: Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine (HVA) in the Treatment of Mixed-Phenotype Acute Leukemia (MPAL), a Multicenter, Prospective, Single-arm Trial

Overview

This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.

Detailed description

Our preliminary studies show that MPAL not only highly expresses BCL-2, but also highly expresses MCL-1, suggesting the need to explore combining MCL-1 inhibitors on the basis of Ven and HMAs. Our preliminary research confirmed that homoharringtonine (HHT) significantly enhances the anti-leukemia effect of Ven/AZA via inhibition of MCL-1. Originally, we designed the HVA regimen by combining HHT with Ven/AZA for the treatment of AML, and achieved better efficacy and safety. Then we exploratively treated 11 MPAL patients with HVA regimen and acquired promising response and safety. In this study, we conduct a multicenter, prospective, single arm trial to evaluate the efficacy and safety of HVA in the treatment of newly diagnosed MPAL.

Interventions

  • Drug HVA
    HVA regimen: Venetoclax: 100 mg on day 1, 200 mg on Day 2, 400 mg per day from Day 3 to Day 14; Azacitidine: 75 mg/m2 per day by subcutaneous injection from Day 1 to Day 7; Homoharringtonine : 1mg/m2 per day by intravenous infusion from Day 1 to Day 7. If co-administered with CYP3A inhibitors, the dose of venetoclax was adjusted in accordance with prescribing recommendations. Fms-related receptor tyrosine kinase 3 (FLT3) inhibitors were recommended in patients with FLT3-ITD/TKD mutations. Also t

Primary outcome measures

  • Composite Complete Remission (CRc) [Time frame: At the end of cycle 2 (28 days for a cycle)]
Secondary outcome measures (4)
  • Complete remission (CR) [Time frame: At the end of cycle 2 (28 days for a cycle)]
  • Overall response rate (ORR) [Time frame: At the end of cycle 2 (28 days for a cycle)]
  • Rate of Measurable residual disease (MRD) negative [Time frame: At the end of cycle 2 (28 days for a cycle)]
  • Adverse events [Time frame: At the end of cycle 2 (28 days for a cycle)]

Eligibility criteria

Inclusion criteria

  • The patient fully understands this study, voluntarily participates, and signs the informed consent form (ICF);
  • Age ≥18 years;
  • Newly diagnosed with MPAL according to the World Health Organization (WHO) 2022 classification.
  • The patient has not started anti-leukemia treatment after the initial diagnosis (except cytoreductive therapy, such as hydroxyurea or cytarabine <1.0 g/day or glucocorticoids);
  • Expected survival ≥12 weeks;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
  • Normal cardiac function, left ventricular ejection fraction ≥50%; normal renal function: creatinine clearance ≥30 ml/min; normal liver function: ALT <5 times the normal value, bilirubin <3 times the normal value;

Exclusion criteria

  • Patients who have had or currently have other malignant tumors requiring treatment;
  • Patients with central nervous system (CNS) infiltration;
  • Other clinically significant uncontrolled conditions, including but not limited to: (1) uncontrolled or active systemic infections (viral, bacterial, or fungal); (2) chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) requiring treatment; (3) uncontrolled hypertension, etc.;
  • Patients who cannot take oral medications or have malabsorption syndrome;
  • Patients with a known history of immediate or delayed hypersensitivity reactions to drugs of the same class as the study medication or to excipients;
  • Pregnant or breastfeeding women, or patients who refuse to use effective contraception during the study;
  • Patients with a history of severe neurological or psychiatric disorders who cannot understand or comply with the study protocol;
  • Patients with severe heart disease, such as myocardial infarction, severe or unstable angina, severe arrhythmias;
  • Patients known to be infected with human immunodeficiency virus (HIV); patients with active hepatitis B or C; subjects who are inactive hepatitis carriers or whose viral hepatitis titers are low after treatment with non-prohibited antiviral drugs are not excluded;
  • Patients who cannot take oral medications or have malabsorption syndrome;
  • Patients whom the investigator determines are unsuitable to participate in this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Department of Hematology, Guangdong Second Provincial General Hospital — Guangzhou

Identifiers

NCT: NCT07517510 · GD2H-2026-571

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗